TOP STORIES
respiratory
ILD

ILD Registry to deliver local and global benefit

The Australasian ILD Registry (AILDR), a bi-national registry of patients with all ILD subtypes, has the potential to address major research questions including around new therapeutics and biomarkers of disease. A pilot phase of the Registry, based at just four sites...

The Australasian ILD Registry (AILDR), a bi-national registry of patients with all ILD subtypes, has the potential to address major...

Read more
medical education

Specialist consultations a positive experience for most – but not all – patients

Specialist get high marks for listening, showing respect and spending enough time with their patients, although perceptions tend to be less positive for younger people and those with multiple chronic conditions, according to a new report. Findings from a survey...

Specialist get high marks for listening, showing respect and spending enough time with their patients, although perceptions tend to be...
COVID-19

Convalescent plasma for COVID-19: enthusiasm has outweighed the evidence

Hospitalised patients with moderate COVID-19 gain no benefit from convalescent plasma on progression to severe disease or mortality, new research shows. The findings of an open-label RCT published in the BMJ further weaken any case for any effect of serum...

Hospitalised patients with moderate COVID-19 gain no benefit from convalescent plasma on progression to severe disease or mortality, new research...
Cystic fibrosis

Study supports use of ivacaftor in first year of life for children with CF

The CFTR modulator therapy ivacaftor (Kalydeco) may be safely used in the first year of life to treat the underlying cause of cystic fibrosis, latest results from the ARRIVAL study suggest. Currently listed on the PBS for use in children...

The CFTR modulator therapy ivacaftor (Kalydeco) may be safely used in the first year of life to treat the underlying...